Ali Bahari1, Seyed Kazem Nezam1, Mehrbod Karimi2,
Kourosh Firouzeh3, Farzad Firouzi4
1 Department of Gastroenterology,
2 Department of Pathology,
3 Department of Internal Medicine,
4 Research Center for Gastroenterology and Liver Disease,
ABSTRACT
Aim:
To comparing furazolidone
and tetracycline in quadruple therapy for eradication of helicobacter pylori
in dyspepsia patients.
Background:
Helicobacter pylori eradication is the main step in dyspepsia and peptic
ulcer management. In
Patients and methods: Dyspeptic patients were randomly assigned in 2 groups and received
omeprazole 20mg/twice a day, bismuth subcitrate 200mg/q6h, amoxicillin
1000mg/twice a day in association with furazolidone 100mg/ twice a day
(OAB-F regimen) or tetracycline 500mg/ twice a day (OAB-T regimen). Stool
antigen test was used to detect H. pylori eradication.
Results:
Totally, 100 patients completed the desired regimen including 49 in OAB-F
and 51 in OAB-T regimen. Following the first week, H. pylori was eradicated
in 97.9% of OAB-F and 96% of OAB-T subjects, however, the difference did not
reach a statistical significant level. These figures were 85.7% and 80.4%
following the 4th week, respectively (NS).
Conclusion:
Both furazolidone-and tetracycline-based quadruple therapy were revealed to
be effective for eradication of H.pylori, however, furazolidone is suggested
for population resistant to metronidazole since it is cheaper and more
available.
Keywords: Furazolidone, Tetracycline, Helicobacter pylori,
Eradication, Dyspepsia.
(Gastroenterology and Hepatology from bed to bench 2008;1(1):39-43).
INTRODUCTION
Helicobacter
pylori (H. pylori) infection is by far the most common chronic bacterial
infection among humans (1). In developing countries, it is more frequent and
occurs earlier (1). Approximately, 80% of adults residing in developing
countries are affected (1,2). Chronic gastritis is usually detected during
endoscopy, however, H. pylori infection is strongly associated with peptic
ulcer, adenocarcinoma of stomach and gastric MALToma (3-8). Therefore, prompt
diagnosis and appropriate management is of utmost importance.
H. pylori infection is diagnosed by either invasive
(endoscopy and biopsy) or non-invasive (urease breath test (UBT), serology, and
stool antigen testing) techniques. Nevertheless, non-invasive techniques
including serology and stool antigen are usually applied for early diagnosis
while UBT is used for eradication follow up (9,10).
Various regimens have been proposed for H. pylori
eradication, among which triple therapy with a proton pump inhibitor (PPI)(i.e.,
omeprazole) in combination with amoxicillin and clarithromycin or quadruple
therapy with a pump inhibitor, bismuth, metronidazole and tetracycline are more
commonly appreciated. However, proposed regimens have limitations including
expenses, availability, drug side effects, patient’s tolerance, and
microorganism resistance, thus, investigations are still continuing to find more
tolerable appropriate regimens. Furazolidone has been studied in scanty
researches (11-17), however, with respect to H. pylori resistance to
metronidazole among Iranian patients (18-20) and availability of furazolidone,
the present study was conducted to compare furazolidone and tetracycline in
quadruple therapy for eradication of H. pylori in Iranian dyspepsia patients.
PATIENTS and METHODS
This double-blinded randomized clinical trial was
conducted during a 6-month period in Khatam hospital in Zahedan. Patients with
gastrointestinal manifestations including heart burn, flatulence, and post-prandial
nausea were visited by an expert gastroenterologist. The following exclusion
criteria were applied at baseline: age >50 years, weight loss >10% during the
past 6 months, severe anorexia, dysphagia, odynophagia, anemia, jaundice,
abdominal mass, lymphadenopathy, family history of gastric or esophageal cancer,
past history of gastric surgery, recurrent vomiting, hematemesis, prior history
of H. pylori treatment, antibiotic treatment during the 4 weeks prior to the
study or treatment with pump inhibitors during the week before the study.
Included patients were those who were positive for both
serum IgG against H. pylori (Serum Anti-H.Pylori IgG, DIAPLUS,
All patients were requested to complete an informed
consent. A checklist of demographic, laboratory, and pathologic features was
completed prior to the commencement of therapy and during follow up. Data were
analyzed by SPSS for Windows (version 10.5,
RESULTS
Totally, 109 patients were enrolled, of whom 9 were
excluded. Fortunately, none of the subjects developed life threatening side
effects, however, minor tolerable complications including, pruritus, nausea, and
vomiting occurred. Finally, 49 patients (26 males and 23 females) in group A
versus 51 patients (32 males and 19 females) in group B completed the desired
regimen. The mean age of the patients was 28.7±6.3 and 28.3±6.3 years in group A
and B, respectively.
Table 1.
Response to therapy based on stool antigen negativity after 1 and 4 weeks of
therapy
|
No. of patients |
Negativity of stool antigen after
the 1st week |
Negativity of stool antigen after
the 4th week |
OAB-F |
49 |
48(97.9%) |
42(85.7%) |
OAB-T |
51 |
49(96.0%) |
41(80.4%) |
OAB-F:
Omeprazole/Amoxicillin/Bismuth/Furazolidone
OAB-T:
Omeprazole/Amoxicillin/Bismuth/Tetracycline
DISCUSSION
Studies
conducted in developing countries demonstrated the increasing frequency of H.
pylori infection while they showed the necessity for microorganism eradication
through a cheap, tolerable and effective regimen (11).
Our
studied population had functional dyspepsia and underwent noninvasive diagnostic
approach for early diagnosis of H. pylori infection, while diagnostic endoscopy
was not advised based on age of <50 years and lack of alerting symptoms (21).
Serum IgG anti H.pylori is a cheap suitable approach for early diagnosis of H.
pylori. In a metanalysis, sensitivity and specificity of IgG anti H.pylori-ELISA
kit was 85% and 79%, respectively (22). Meanwhile, Stevens et al have reported
an accuracy of 78% for anti H.Pylori ELISA kit in 558 samples (23).
Nevertheless, diagnostic value of serology approaches depends mainly on H.Pylori
prevalence and the underlying etiology (dyspepsia, peptic ulcer, etc.). However,
stool antigen testing and urease breath test (UBT) are preferable to serology
for early diagnosis and follow up (24-26). Therefore, we used serology and stool
antigen testing for early diagnosis and stool antigen testing for follow up.
Vaira et al reported stool antigen test to have sensitivity and specificity of
94% and 86%, respectively (25,26). These figures were 94% and 92% in Trevisani
et al study (27). On the other hand, stool antigen testing was showed to be a
valuable test for eradication follow up, however, the exact timing is a matter
of controversy. Some investigators have proposed the 4th week after
the therapy to be a suitable point (25-28) while Vaira et al reported a positive
predictive value (PPV) of 100% and a negative predictive value (NPV) of 91% if
the test had been offered 1 week following the therapy (26). We advised our
subjects to perform the test at weeks 1 and 4.
Antibiotics, bismuth and PPIs may be associated with false negative stool
antigen testing results (29), however, Makristathis et al reported 32% false
positive results among 41 patients after the 5th week (30).
Prior
investigators have proposed different eradication regimens. Suitable regimens
may be advised based on the following criteria: expenses, side effects,
availability, easy to use, and drug resistance pattern. A combination of
omeprazole, bismuth, metronidazole and tetracycline is usually prescribed,
however, combination of a PPI, clarithromycin, amoxicillin, and metronidazole is
quite common in
REFERENCES
1.
Pounder RE. The
prevalence of Helicobacter pylori infection in different countries. Aliment
Pharmacol Ther 1995; 9(Suppl 2):33-39.
2.
Torres J,
Leal-Herrera Y, Perez-Perez G, et al. A community-based seroepidemiologic study
of Helicobacter pylori infection in
3.
Dunn BE, Cohen H,
Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720–41.
4.
The EUROGAST
Study Group, An international association between Helicobacter pylori infection
and gastric cancer. Lancet 1993;341:1359.
5.
Parsonnet J,
Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk
of gastric carcinoma. N Engl J Med 1991;325:1127-31.
6.
Nomura A,
Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and gastric
carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325:1132-36.
7.
Wotherspoon AC,
Ortiz-Hidalgo C, Falzon M, et al. Helicobacter pylori-associated gastritis and
primary B-cell gastric lymphoma. Lancet 1991; 338:1175-76.
8.
Parsonnet J,
Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric
lymphoma. N Engl J Med 1994; 330:1267-71.
9.
Malfertheiner P,
Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter
pylori infection. The
10.
Perri F, Manes G,
Neri M, et al. Helicobacter pylori antigen stool test and 13C-urea breath test
in patients after eradication treatments. Am J Gastroenterol 2002; 97:2756.
11.
Fakheri H,
Malekzadeh R, Merat S, et al. Clarithromycin vs. furazolidone in quadruple
therapy regimens for the treatment of Helicobacter pylori in a population with a
high metronidazole resistance rate. Aliment Pharmacol Ther 2001;15:411-16.
12.
Eisig JN,
Silva FM,
Rodriguez TN, et al. A furazolidone-based quadruple therapy for
Helicobacter pylori retreatment in patients with peptic ulcer disease.
Clinics 2005 ;60(6):485-8.
13.
Huo
XH,
Chu
JK,
Yang XF, et al. Efficacy of one-day quadruple therapy for H pylori
infection in Chinese patients.
World J Gastroenterol 2006;12(19):3105-7.
14.
Khatibian M,
Ajvadi Y,
Nasseri-Moghaddam S, et al. Furazolidone-based, metronidazole-based,
or a combination regimen for eradication of Helicobacter pylori in peptic ulcer
disease.
Arch Iran Med 2007; 10(2):161-7.
15.
Kawakami E,
Machado RS,
Ogata SK,et al. Furazolidone-based triple therapy for H pylori
gastritis in children.
World J Gastroenterol 2006; 12(34):5544-9.
16.
Nijevitch AA,
Shcherbakov PL,
Sataev VU, et al. Helicobacter pylori eradication in childhood after
failure of initial treatment: advantage of quadruple therapy with nifuratel to
furazolidone.
Aliment Pharmacol Ther 2005;22(9):881-7.
17.
Daghaghzadeh H,
Emami MH,
Karimi S, et al. One-week versus two-week furazolidone-based
quadruple therapy as the first-line treatment for Helicobacter pylori infection
in Iran.
J
Gastroenterol Hepatol 2007;22(9):1399-403.
18.
Fallahi GH,
Maleknejad S. Helicobacter pylori culture and antimicrobial
resistance in
19.
Rafeey M,
Ghotaslou R,
Nikvash S,et al. Primary resistance in Helicobacter pylori isolated
in children from Iran.
J
Infect Chemother 2007; 13(5):291-5.
20.
Siavoshi F,
Safari F,
Doratotaj D, et al. Antimicrobial resistance of Helicobacter pylori
isolates from Iranian adults and children.
Arch Iran Med 2006; 9(4):308-14.
21.
Talley N,
22.
23.
Stevens M, Livsey
S, Swann R, editors. Evaluation of sixteen EIAs for the detection of antibodies
to Helicobacter pylori.
24.
Buzás
GM,
Józan J. Nitrofuran-based regimens for the eradication of
Helicobacter pylori infection.
J
Gastroenterol Hepatol 2007;22(10):1571-81
25.
Vaira D,
Malfertheiner P, Megraud F, et al. Diagnosis of Helicobacter pylori infection
with a new non-invasive antigen-based assay. HpSA European study group. Lancet
1999;354:30-33.
26.
Vaira D, Vakil N,
Menegatti M, et al. The stool antigen test for detection of Helicobacter pylori
after eradication therapy. Ann Intern Med 2002; 136:280-87.
27.
Trevisani L,
Sartori S, Galvani F, et al. Evaluation of a new enzyme immunoassay for
detecting Helicobacter pylori in feces: A prospective pilot study. Am J
Gastroenterol 1999; 94:1830-33.
28.
Manes G, Balzano
A, Iaquinto G, et al. Accuracy of stool antigen test in posteradication
assessment of Helicobacter pylori infection. Dig Dis Sci 2001; 46:2440-44.
29.
Bravo LE, Realpe
JL, Campo C, et al. Effects of acid suppression and bismuth medications on the
performance of diagnostic tests for Helicobacter pylori infection. Am J
Gastroenterol 1999; 94:2380-83.
30.
Makristathis A,
Pasching E, Schutze K, et al. Detection of Helicobacter pylori in stool
specimens by PCR and antigen enzyme immunoassay. J Clin Microbiol 1998;
36:2772-74.
31.
Osato MS, Reddy
R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to
metronidazole or clarithromycin in the
32.
Meyer JM,
Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resitance in
the
33.
Safaralizadeh R,
Siavoshi F,
Malekzadeh R, et al. Antimicrobial effectiveness of furazolidone
against metronidazole-resistant strains of Helicobacter pylori.
East Mediterr Health J 2006;12(3-4):286-93.
34.
Qasim A,
Sebastian S, Thornton O, et al. Rifabutin- and furazolidone-based Helicobacter
pylori eradication therapies after failure of standard first- and second-line
eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005;21:91-6.
35.
Malekzadeh R,
Ansari R,
Vahedi H, et al. Furazolidone versus metronidazole in quadruple
therapy for eradication of Helicobacter pylori in duodenal ulcer disease.
Aliment Pharmacol Ther 2000;14(3):299-303.
36.
Fakheri H,
Malekzadeh R, Merat S, et al. Clarithromycin vs. furazolidone in quadruple
therapy regimens for the treatment of Helicobacter pylori in a population with a
high metronidazole resistance rate. Aliment Pharmacol Ther 2001;15:411-15.